Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Disease Presentation and Remission Rate in Graves’ Disease Treated With Antithyroid Drugs: Is Gender Really a Factor?
source: Endocrine Practice
year: 2019
authors: Diker-Cohen T, Duskin-Bitan H, Shimon I, Hirsch D, Akirov A, Tsvetov G, Robenshtok E
summary/abstract:Objective:
Male gender is considered an adverse prognostic factor for remission of Graves disease treatment with antithyroid drugs (ATDs), although published data are conflicting. This often results in early consideration of radioiodine treatment and surgery for men. Our objective was to compare disease presentation and outcome in men versus women treated with ATDs.
Methods:
Retrospective study of 235 patients (64 men, 171 women) with Graves disease who were evaluated for features at presentation and outcome at the end of follow-up between 2010 and 2015.
Results:
Disease presentation was similar in men and women for age at diagnosis (41.4 ± 14 years vs. 40 ± 15 years), duration of follow-up (6.6 ± 7 years vs. 7.7 ± 6 years), rates of comorbid autoimmune diseases, and rate of Graves ophthalmopathy. Smoking was more prevalent in males (31% vs. 15%; P = .009). Free thyroxine and triiodothyronine levels were comparable. ATDs were first-line treatment in all males and in 168 of 171 females, for a median duration of 24 and 20 months, respectively ( P = .55). Remission rates were 47% in men and 58% in women ( P = .14). Males had fewer adverse events (9% vs. 18%) and treatment discontinuation (5% vs. 16%). Disease recurrence was comparable (14% vs. 20%; P = .32), as was requirement for second-line treatment, either radioiodine therapy or thyroidectomy.
Conclusion:
Graves disease presentation is similar in men and women. Men treated with ATDs have high remission rates and similar recurrence rates compared to women, with fewer adverse events and less discontinuation of treatment. ATDs are an attractive first-line treatment for both genders.
DOI: 10.4158/EP-2018-0365
read more full text
myBinderRelated Content
-
Relation between Therapy Options for Graves’ Disease and the Course of Graves’ Ophthalmopathy: A Systema...Background: The relation between therap...
-
Recurrence of Graves’ Disease is Predicted by Lower Patient Age at Initial Diagnosis: Implications for CareOne of the greatest challenges in managi...
-
The Second Antithyroid Drug Treatment is Effective in Relapsed Graves’ Disease Patients: A Median 11-Year Foll...Background: Antithyroid drug (ATD) is a...
-
Current Trends in Antithyroid Drug Treatment of Graves’ DiseaseIntroduction: Graves' hyperthyroidism i...
-
Thyroglobulin Autoantibodies are Associated With Refractoriness to Antithyroid Drug Treatment for Graves’ Dise...Objective: The recurrence rate associat...
-
Radioiodine Therapy Versus Antithyroid Medications for Graves’ DiseaseBackground: Graves' disease is the most...
-
TSH-Receptor Autoimmunity in Graves’ Disease After Therapy With Anti-Thyroid Drugs, Surgery, or Radioiodine: A...Introduction: Autoimmunity against the ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google